45660-95-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-3-(chloromethyl)pyrazine is utilized as a key intermediate in the synthesis of various medicinal compounds. Its unique reactivity allows for the development of new pharmaceuticals with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-3-(chloromethyl)pyrazine is employed as a building block in the production of pesticides. Its incorporation into these compounds contributes to the development of more effective and targeted pest control solutions.
Used in Organic Synthesis:
2-Chloro-3-(chloromethyl)pyrazine is used as a versatile reagent in organic synthesis reactions. Its unique structural properties enable the formation of a wide range of chemical compounds, expanding the scope of synthetic chemistry.
Used in Specialty Chemicals Production:
This chemical compound is also recognized for its potential use as a reagent in the manufacturing of specialty chemicals. Its unique reactivity and structural properties contribute to the development of high-value chemical products with specific applications in various industries.

Upstream product

• 105985-13-5 1-hydroxy-3-methyl-2(1H)-pyrazinone 
• 121246-96-6 3-chloro-2-pyrazinecarboxaldehyde 
• 95-58-9 2-chloro-3-methylpyrazine 
• 89283-32-9 (3-chloropyrazin-2-yl)methanol 

Downstream Products

• 867165-55-7 2-((3-chloropyrazin-2-yl)methyl)isoindoline-1,3-dione 

Relevant academic research and scientific papers

Preparation of HIF-2alpha small-molecule inhibitor and application thereof

The invention belongs to the technical field of medicines, and relates to an HIF-2 alpha small-molecule inhibitor as well as a preparation method and an application thereof. The HIF-2alpha small-molecule inhibitor is a compound as shown in a structural general formula I and a stereoisomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a prodrug thereof. According to the invention, molecular simulation drug design software MOE is used for screening and molecular docking of pharmacophores, according to a final docking dominant structure and an isosteric principle, a series of compounds are designed and synthesized, and an in-vitro anti-tumor activity screening test shows that the compounds have anti-tumor activity. The HIF-2 alpha small-molecule inhibitor provided by the invention has a relatively good application prospect in the aspect of preventing or treating cancers, particularly glioma.

NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone deriva

TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142.

Process to prepare substituted imidazopyrazine compounds

A method of preparing wherein, X=Cl, Br, I, comprises the step of treating with N-chloro-, N-bromo-, or N-iodosuccinimide in a compatible solvent such as dimethylformamide (DMF) at 0-60° C. followed by halogenation.

Studies on Pyrazines. 13. Chlorination of 1-Hydroxy-2(1H)-pyrazinones with Phosphoryl Chloride. Formation of 2,5-Dichloro-3-phenylpyrazine from 1-Hydroxy-3-phenyl-2(1H)-pyrazinone

The chlorination of 1-hydroxy-3-phenyl-2(1H)-pyrazinone with phosphoryl chloride proceeded to 5-chloro-3-phenyl-2(H)-pyrazinone or 2,5-dichloro-3-phenylpyrazine on heating to elevated temperatures.To define the mechanism of the novel formation, reactions

PHARMACOLOGICALLY ACTIVE GUANIDINE COMPOUNDS

The compounds are substituted thioalkyl-, aminoalkyl-and oxyalkyl-guanidines which are inhibitors of histamine activity.

PHARMACOLOGICALLY ACTIVE THIOUREA AND UREA COMPOUNDS

The compounds are substituted thioalkyl-, aminoalkyl-and oxyalkyl-thioureas and ureas which are inhibitors of histamine activity.